• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
9.20% $12.43

NEUREN PHARMACEUTICALS LIMITED - Corporate Spotlight

Market Cap $1.730B  ! watchlist Created with Sketch. Add to my watchlist

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
$12.43 		Change
-1.260(9.20%) 		Mkt cap ! $1.730B
Open High Low Value Volume
$13.58 $13.68 $12.42 $14.83M 1.147M

Buyers (Bids)

No. Vol. Price($)
3 2928 $12.43
 

Sellers (Offers)

Price($) Vol. No.
$12.46 670 1
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$12.47 		  Change
-1.260 ( 9.34 %)
Open High Low Volume
$13.52 $13.67 $12.43 185284
Last updated 15.59pm 21/11/2024 ?
NEU (ASX) Chart

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.